“Tissue-selective estrogen complex” or TSEC is a novel concept of estrogen replacement therapy for the postmenopause based on the combined use of estrogens and selective estrogen receptor modulators (SERMs). The aim of this study was to exploit the potential of a novel transgenic mouse where luciferase expression is associated with cell proliferation (the MITO-luc mouse) to investigate cell proliferation in reproductive and nonreproductive tissues in mice exposed to repetitive treatments with TSEC.
Material and Methods:
Ovariectomized MITO-Luc mice were subjected to a daily oral treatment with bazedoxifene, conjugated estrogen (CE), TSEC, or raloxifene for 21 days. During the treatment, the proliferative effects of treatments were monitored by bioluminescence-based in vivo imaging. At the end of the treatment, mice were euthanized and cell proliferation assessed in selected tissues by quantitative analysis of luciferase activity and by immunohistochemistry (IHC).
Results:
In uterus treatment with CE, but not TSEC, induced a large increase in luciferase activity underlying the proliferative effect of the hormone. No accumulation of luciferase was observed in other organs and tissues target of estrogen action. We observed an increase of Ki67 immunoreactivity only in the uterus of mice treated with CE.
Conclusion:
Pairing of an SERM with estrogens results in a complete blockage of CE proliferative effects in uterus and the absence of any undesired proliferative effects in other organs; moreover, the MITO-Luc mouse is an efficacious tool for the global, rapid, and reliable analysis of drug-induced proliferation.
KregeJHHodginJBCouseJF. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A. 1998; 95(26): 15677–15682.
2.
JonesMEThorburnAWBrittKL. Aromatase-deficient (ArKO) mice have a phenotype of increased adiposity. Proc Natl Acad Sci U S A. 2000; 97(23): 12735–12740.
3.
CianaPRaviscioniMMussiP. In vivo imaging of transcriptionally active estrogen receptors. Nat Med. 2003; 9(1): 82–86.
4.
KorachKSEmmenJMWalkerVR. Update on animal models developed for analyses of estrogen receptor biological activity. J Steroid Biochem Mol Biol. 2003; 86(3-5): 387–391.
5.
DerooBJKorachKS. Estrogen receptors and human disease. J Clin Invest. 2006; 116(3): 561–570.
6.
ImaiYKondohSKouzmenkoAKatoS. Regulation of bone metabolism by nuclear receptors. Mol Cell Endocrinol. 2009; 310(1-2): 3–10.
7.
CauleyJARobbinsJChenZ. Women's Health Initiative Investigators. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trialJAMA. 2003; 290(13): 1729–1738.
8.
NadalARoperoABLaribiOMailletMFuentesESoriaB. Nongenomic actions of estrogens and xenoestrogens by binding at a plasma membrane receptor unrelated to estrogen receptor alpha and estrogen receptor beta. Proc Natl Acad Sci U S A. 2000; 97(21): 11603–11608.
9.
Della TorreSRandoGMedaC. Amino acid-dependent activation of liver estrogen receptor alpha integrates metabolic and reproductive functions via IGF-1. Cell Metab. 2011; 13(2): 205–214.
10.
StraubRH. The complex role of estrogens in inflammation. Endocr Rev. 2007; 28(5): 521–574.
11.
VegetoEBelcreditoSEtteriS. Estrogen receptor-alpha mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci U S A. 2003; 100(16): 9614–9619.
12.
MaggiACianaPBelcreditoSVegetoE. Estrogens in the nervous system: mechanisms and nonreproductive functions. Annu Rev Physiol. 2004; 66: 291–313.
13.
BurgerHG. The endocrinology of the menopause. Maturitas. 1996; 23(2): 129–136.
14.
GreendaleGAWellsBMarcusRBarrett-ConnorE. How many women lose bone mineral density while taking hormone replacement therapy? Results from the Postmenopausal Estrogen/Progestin Interventions Trial. Arch Intern Med. 2000; 160(20): 3065–3071.
EspelandMAMarcovinaSMMillerV. Effect of postmenopausal hormone therapy on lipoprotein(a) concentration. PEPI Investigators. Postmenopausal Estrogen/Progestin Interventions. Circulation. 1998; 97(10): 979–986.
17.
LoboRABushTCarrBRPickarJH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril. 2001; 76(1): 13–24.
18.
VogelvangTEvan der MoorenMJMijatovicV. Hormone replacement therapy, selective estrogen receptor modulators, and tissue-specific compounds: cardiovascular effects and clinical implications. Treat Endocrinol. 2004; 3(2): 105–115.
19.
BolegoCVegetoEPinnaCMaggiACignarellaA. Selective agonists of estrogen receptor isoforms: new perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol. 2006; 26(10): 2192–2199.
20.
LeonRLHuberJDRosenCL. Potential age-dependent effects of estrogen on neural injury. Am J Pathol. 2011; 178(6): 2450–2460.
21.
BachmannGANevadunskyNS. Diagnosis and treatment of atrophic vaginitis. Am Fam Physician. 2000; 61(10): 3090–3096.
22.
SucklingJLethabyAKennedyR. Local estrogen for vaginal atrophy in postmenopausal women. Cochrane Database Syst Rev. 2006;18(4):(CD001500).
23.
North American Menopause Society. Management of osteoporosis in postmenopausal women: 2006 position statement of The North American Menopause Society. Menopause. 2006; 13(3): 340–367.
24.
TannenRLWeinerMGXieDBarnhartK. Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod. 2007; 22(6): 1769–1777.
25.
PalaciosS. The future of the new selective estrogen receptor modulators. Menopause Int. 2007; 13(1): 27–34.
26.
McDonnellDPChangCYNorrisJD. Capitalizing on the complexities of estrogen receptor pharmacology in the quest for the perfect SERM. Ann N Y Acad Sci. 2001; 949: 16–35.
27.
FrasorJStossiFDanesJMKommBLyttleCRKatzenellenbogenBS. Selective estrogen receptor modulators: discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res. 2004; 64(4): 1522–1533.
28.
Buelke-SamJBryantHUFrancisPC. The selective estrogen receptor modulator, raloxifene: an overview of nonclinical pharmacology and reproductive and developmental testing. Reprod Toxicol. 1998; 12(3): 212–221.
29.
InalMMIncebiyikASanciM. Ovarian cysts in tamoxifen-treated women with breast cancer. Eur J Obstet Gynecol Reprod Biol. 2005; 120(1): 104–106.
KharodeYBodinePVMillerCPLyttleCRKommBS. The pairing of a selective estrogen receptor modulator, bazedoxifene, with conjugated estrogens as a new paradigm for the treatment of menopausal symptoms and osteoporosis prevention. Endocrinology. 2008; 149(12): 6084–6091.
32.
KommBS. A new approach to menopausal therapy: the tissue selective estrogen complex. Reprod Sci. 2008; 15(10): 984–992.
33.
KharodeYBodinePVMillerCPLyttleCRKommBS. The Pairing of a Selective Estrogen Receptor Modulator, Bazedoxifene, with Conjugated Estrogens as a New Paradigm for the Treatment of Menopausal Symptoms and Osteoporosis Prevention. Endocrinology. 2008; 149(12): 6084–6091.
34.
KommBSVlasserosFSamadfamRChouinardLSmithSY. Skeletal effects of bazedoxifene paired with conjugated estrogens in ovariectomized rats. Bone. 2011; 49(3): 376–386.
35.
PeanoBJCrabtreeJSKommBSWinnekerRCHarrisHA. Effects of various selective estrogen receptor modulators with or without conjugated estrogens on mouse mammary gland. Endocrinology. 2009; 150(4): 1897–1903.
36.
PinkertonJVUtianWHConstantineG. SMART-2: a phase III study of the efficacy and safety of bazedoxifene/conjugated estrogens for the treatment of menopausal vasomotor. Menopause. 2007; 14: 1081.
37.
GoemanF.ManniIArtusoI. Molecular imaging of Nuclear Factor-Y transcriptional activity maps proliferation sites in live animals. Mol Biol Cell. 2012Feb 29. [Epub ahead of print].
38.
ManniIMazzaroGGurtnerA. NF-Y mediates the transcriptional inhibition of the cyclin B1, cyclin B2, and cdc25C promoters upon induced G2 arrest. J Biol Chem. 2001; 276(8): 5570–5576.
39.
ImbrianoCGurtnerACocchiarellaF. Direct p53 transcriptional repression: in vivo analysis of CCAAT-containing G2/M promoters. Mol Cell Biol. 2005; 25(9): 3737–3751.
40.
RandoGBiserniACianaPMaggiA. Profiling of drug action using reporter mice and molecular imaging. Methods Mol Biol. 2010; 602: 79–92.
41.
CianaPDi LuccioGBelcreditoS. Engineering of a mouse for the in vivo profiling of estrogen receptor activity. Mol Endocrinol. 2001; 15(7): 1104–1113.
42.
StellABelcreditoSCianaPMaggiA. Molecular imaging provides novel insights on estrogen receptor activity in mouse brain. Mol Imaging. 2008; 7(6): 283–292.
43.
KommBSLyttleCR. Developing a SERM: stringent preclinical selection criteria leading to an acceptable candidate (WAY-140424) for clinical evaluation. Ann N Y Acad Sci. 2001; 949: 317–326.
44.
KommBSKharodeYPBodinePVHarrisHAMillerCPLyttleCR. Bazedoxifene acetate: a selective estrogen receptor modulator with improved selectivity. Endocrinology. 2005; 146(9): 3999–4008.
45.
ArunBAnthonyMDunnB. The search for the ideal SERM. Expert Opin Pharmacother. 2002; 3(6): 681–691.
46.
BiserniAGiannessiFSciarroniAFMilazzoFMMaggiACianaP. In vivo imaging reveals selective peroxisome proliferator activated receptor modulator activity of the synthetic ligand 3-(1-(4-chlorobenzyl)-3-t-butylthio-5-isopropylindol-2-yl)-2,2-dimethylpropanoic acid (MK-886). Mol Pharmacol. 2008; 73(5): 1434–1443.
